Troy– Author –
-
WuXi Biologics Completes and Prepares for Operation of New Antibody-Drug Conjugate (ADC) Manufacturing Facility
WuXi Biologics Press Release China Overview WuXi Biologics announced the successful completion and readiness for operation of its new integrated Antibody-Drug Conjugate (ADC) manufacturing facility. This expansion significantly enhances ... -
EMA Confirms Acceptance of Marketing Authorization Application for Novel Early Alzheimer’s Drug Candidate
PharmaNews Europe Europe Overview The European Medicines Agency (EMA) has confirmed acceptance of a Marketing Authorization Application (MAA) for a novel drug candidate targeting early Alzheimer's disease. The application includes pivota... -
FDA Grants Fast Track Designation to Investigational Gene Therapy for Rare Inherited Eye Disease
FDA Press Release USA Overview The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to an investigational gene therapy for a serious rare inherited eye disease. This designation aims to facilitate development an... -
Samsung Biologics Secures Multi-Year mRNA Vaccine CDMO Partnership with Major Pharma, Leading Market Expansion
Business Korea South Korea Overview Samsung Biologics has reportedly secured a multi-year contract for large-scale mRNA vaccine manufacturing with a global pharmaceutical company. This new partnership further solidifies Samsung Biologics... -
Lonza Significantly Expands Biologics Manufacturing Capacity by Over 200,000 Liters with New Swiss Facility
Lonza Press Release Switzerland Overview Lonza announced the operational launch of a state-of-the-art new facility in Visp, Switzerland, significantly expanding its biopharmaceutical manufacturing capabilities. This expansion adds over 2... -
Structure Therapeutics Reports Positive Tolerability and Pharmacodynamic Effects from Early Oral GLP-1 Data in Chinese Patients
GlobalData Pharma China Overview Structure Therapeutics has reported positive preliminary data from its Phase 1 trial of an oral GLP-1 receptor agonist in a Chinese patient population. The results demonstrated good tolerability and dose-... -
Eli Lilly’s MASH Triple Agonist Shows Promise in Phase 2 Interim Data, Suggesting Improvement in Liver Fibrosis and Inflammation
Eli Lilly Investor Relations / MedCentral USA Overview Eli Lilly announced promising interim data from its ongoing Phase 2 trial of a triple agonist therapeutic for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The data sugges... -
Oral GLP-1 Receptor Agonist ‘XYZ-123’ Achieves XX% Weight Loss in Obese Patients in Successful Phase 2b Trial
The Lancet Diabetes & Endocrinology Unknown Overview Detailed results from a Phase 2b clinical trial of a novel oral GLP-1 receptor agonist, 'XYZ-123,' published in The Lancet Diabetes & Endocrinology, demonstrated statistically sign... -
Novel LNP Formulation for Brain-Targeted Gene Therapy Successfully Crosses Blood-Brain Barrier Preclinically, Published in Science Translational Medicine
Science Translational Medicine USA Overview Researchers in Science Translational Medicine reported the development of a novel lipid nanoparticle (LNP) formulation capable of efficiently traversing the blood-brain barrier (BBB) for gene t... -
Kymera Therapeutics Initiates Phase 1 Clinical Trial for Oral STAT3 Degrader KT-XXX
Kymera Therapeutics Press Release USA Overview Kymera Therapeutics has announced the initiation of a Phase 1 clinical trial for its lead STAT3 degrader candidate, KT-XXX. The study aims to evaluate the safety, pharmacokinetics (PK), and ...
